Free Access
Med Sci (Paris)
Volume 34, Number 2, Février 2018
Page(s) 155 - 160
Section M/S Revues
Published online 16 February 2018
  1. Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101 : 38-44. [CrossRef] [PubMed] [Google Scholar]
  2. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118 : 1881-5. [Google Scholar]
  3. Park SJ, Oh CM, Kim BW, et al. Nationwide incidence of ocular melanoma in South Korea by using the National Cancer Registry Database (1999-2011). Invest Ophthalmol Vis Sci 2015; 56 : 4719-24. [CrossRef] [PubMed] [Google Scholar]
  4. Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol 2015; 99 : 1550-3. [Google Scholar]
  5. Furney SJ, Pedersen M, Gentien D, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013; 3 : 1122-9. [Google Scholar]
  6. Royer-Bertrand B, Torsello M, Rimoldi D, et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet 2016; 99 : 1190-8. [Google Scholar]
  7. Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017; 32 : 204-20 e15. [Google Scholar]
  8. Mobuchon L, Battistella A, Bardel C, et al. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. NPJ Genom Med 2017; 2. [Google Scholar]
  9. Ferguson R, Vogelsang M, Ucisik-Akkaya E, et al. Genetic markers of pigmentation are novel risk loci for uveal melanoma. Sci Rep 2016; 6 : 31191. [Google Scholar]
  10. Cassoux N, Rodrigues MJ, Plancher C, et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol 2014; 98 : 769-74. [Google Scholar]
  11. Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. Nat Genet 2015; 47 : 1402-7. [Google Scholar]
  12. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015; 347 : 78-81. [Google Scholar]
  13. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15 : 585-98. [Google Scholar]
  14. Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 2016; 26 : 300-3. [Google Scholar]
  15. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457 : 599-602. [Google Scholar]
  16. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363 : 2191-9. [Google Scholar]
  17. Moore AR, Ceraudo E, Sher JJ, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 2016; 48 : 675-80. [Google Scholar]
  18. Johansson P, Aoude LG, Wadt K, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 2016; 7 : 4624-31. [Google Scholar]
  19. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330 : 1410-3. [Google Scholar]
  20. Martin M, Masshofer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45 : 933-6. [Google Scholar]
  21. Harbour JW, Roberson ED, Anbunathan H, et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45 : 133-5. [Google Scholar]
  22. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43 : 1018-21. [Google Scholar]
  23. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43 : 1022-5. [Google Scholar]
  24. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013; 92 : 974-80. [Google Scholar]
  25. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010; 465 : 243-7. [Google Scholar]
  26. Hebert L, Bellanger D, Guillas C, et al. Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function. Oncotarget 2017; 8 : 72513-27. [Google Scholar]
  27. Bononi A, Yang H, Giorgi C, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ 2017; 24 : 1694-704. [CrossRef] [Google Scholar]
  28. Johnson CP, Kim IK, Esmaeli B, et al. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One 2017; 12 : e0178189. [Google Scholar]
  29. Dujardin G, Daguenet E, Bernard DG, et al. L’épissage des ARN pré-messagers : quand le splicéosome perd pied. Med Sci (Paris) 2016; 32 : 1103-10. [Google Scholar]
  30. Cretu C, Schmitzova J, Ponce-Salvatierra A, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell 2016; 64 : 307-19. [Google Scholar]
  31. Alsafadi S, Houy A, Battistella A, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun 2016; 7 : 10615. [Google Scholar]
  32. DeBoever C, Ghia EM, Shepard PJ, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3’ splice site selection in SF3B1-mutated cancers. PLoS Comput Biol 2015; 11 : e1004105. [Google Scholar]
  33. Darman RB, Seiler M, Agrawal AA, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3’ splice site selection through use of a different branch point. Cell Rep 2015; 13 : 1033-45. [Google Scholar]
  34. Joshi P, Halene S, Abdel-Wahab O. How do messenger RNA splicing alterations drive myelodysplasia? Blood 2017; 129 : 2465-70. [Google Scholar]
  35. Shirai CL, Ley JN, White BS, et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 2015; 27 : 631-43. [Google Scholar]
  36. Ilagan JO, Ramakrishnan A, Hayes B, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res 2015; 25 : 14-26. [Google Scholar]
  37. Madan V, Kanojia D, Li J, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun 2015; 6 : 6042. [Google Scholar]
  38. Zhang J, Lieu YK, Ali AM, et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci USA 2015; 112 : E4726-34. [Google Scholar]
  39. Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 2015; 27 : 617-30. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.